Publication | Closed Access

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

OncologyPlacebo-controlled Phase 3Metronomic TherapyClinical TrialsGynecologyRecurrent Ovarian CancerAnti-angiopoietin TherapyPharmacotherapyCancer TreatmentMedicineOvarian Cancer